Skip to main content

Table 3 Association of PD-L1 staining with clinicopathologic factors in triple-negative patients without neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 

TC

TCIC

IC

sTIL level

Factors

Negative

Positive

Fisher

Negative

Positive

Fisher

Negative

Positive

Fisher

Low

High

Fisher

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

Age

[N = 60]

 

[N = 59]

 

[N = 59]

 

[N = 59]

 

 < 50 years

13 (87)

2 (13)

0.6339

11 (79)

3 (21)

0.5163

11 (79)

3 (21)

0.5163

6 (43)

8 (57)

0.5378

 ≥ 50 years

41 (91)

4 (9)

 

30 (67)

15 (33)

 

30 (67)

15 (33)

 

15 (33)

30 (67)

 

Race/ethnicity

[N = 60]

 

[N = 59]

 

[N = 59]

 

[N = 59]

 

 Black

13 (81)

3 (19)

0.3966

6 (38)

10 (63)

0.003

6 (38)

10 (63)

0.003

3 (19)

13 (81)

0.1211

 White+Latino

40 (93)

3 (7)

 

34 (81)

8 (19)

 

34 (81)

8 (19)

 

17 (40)

25 (60)

 

 Others

1 (100)

0 (0)

 

1 (100)

0 (0)

 

1 (100)

0 (0)

 

1 (100)

0 (0)

 

Histologic type

[N = 59]

 

[N = 58]

 

[N = 58]

 

[N = 58]

 

 IDC

53 (90)

6 (10)

NA

40 (69)

18 (31)

NA

40 (69)

18 (31)

NA

20 (34)

38 (66)

NA

 Metaplastic

0 (0)

0 (0)

 

0 (0)

0 (0)

 

0 (0)

0 (0)

 

0 (0)

0 (0)

 

Histologic grade

[N = 59]

 

[N = 58]

 

[N = 58]

 

[N = 58]

 

 2

11 (100)

0 (0)

0.582

8 (73)

3 (27)

1

8 (73)

3 (27)

1

5 (45)

6 (55)

0.4866

 3

42 (88)

6 (13)

 

32 (68)

15 (32)

 

32 (68)

15 (32)

 

15 (32)

32 (68)

 

sTIL level

[N = 59]

 

[N = 59]

 

[N = 59]

 

NA

 

 < 10%

21 (100)

0 (0)

0.0796

21 (100)

0 (0)

0.0001

21 (100)

0 (0)

0.0001

   

 ≥ 10%

32 (84)

6 (16)

 

20 (53)

18 (47)

 

20 (53)

18 (47)

    

Tumor size

[N = 59]

 

[N = 58]

 

[N = 58]

 

[N = 58]

 

 ≤ 2 cm

31 (97)

1 (3)

0.14

25 (78)

7 (22)

0.1144

25 (78)

7 (22)

0.1144

14 (44)

18 (56)

0.2326

 > 2 to 5 cm

19 (83)

4 (17)

 

14 (61)

9 (39)

 

14 (61)

9 (39)

 

6 (26)

17 (74)

 

 > 5 cm

3 (75)

1 (25)

 

1 (33)

2 (67)

 

1 (33)

2 (67)

 

0 (0)

3 (100)

 

pN

[N = 59]

 

[N = 58]

 

[N = 58]

 

[N = 58]

 

 (y)pN0

37 (90)

4 (10)

0.7838

30 (73)

11 (27)

0.559

30 (73)

11 (27)

0.559

15 (37)

26 (63)

0.4834

 (y)pN1

11 (85)

2 (15)

 

7 (54)

6 (46)

 

7 (54)

6 (46)

 

3 (23)

10 (77)

 

 (y)pN2

3 (100)

0 (0)

 

2 (67)

1 (33)

 

2 (67)

1 (33)

 

1 (33)

2 (67)

 

 (y)pN3

2 (100)

0 (0)

 

1 (100)

0 (0)

 

1 (100)

0 (0)

 

1 (100)

0 (0)

 

pM

[N = 59]

 

[N = 58]

 

[N = 58]

 

[N = 58]

 

 0

51 (89)

6 (11)

1

39 (68)

18 (32)

1

39 (68)

18 (32)

1

20 (35)

37 (65)

1

 1

2 (100)

0 (0)

 

1 (100)

0 (0)

 

1 (100)

0 (0)

 

0 (0)

1 (100)

 

pStage

[N = 57]

 

[N = 56]

 

[N = 56]

 

[N = 56]

 

 I

26 (93)

2 (7)

0.6264

22 (79)

6 (21)

0.3932

22 (79)

6 (21)

0.3932

12 (43)

16 (57)

0.437

 II

19 (86)

3 (14)

 

13 (59)

9 (41)

 

13 (59)

9 (41)

 

5 (23)

17 (77)

 

 III

4 (80)

1 (20)

 

3 (60)

2 (40)

 

3 (60)

2 (40)

 

2 (40)

3 (60)

 

 IV

2 (100)

0 (0)

 

1 (100)

0 (0)

 

1 (100)

0 (0)

 

0 (0)

1 (100)

 
  1. IDC invasive ductal carcinoma, sTIL stromal tumor infiltrating lymphocytes